

# First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

NCT07136779

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	VelaVigo Bio Inc
Enrollment	310 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- \. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.
- \. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or is intolerable with standard treatment, or for which no standard treatment is available
- \. At least one measurable lesion as assessed by the investigator according to RECIST v1.1 criteria
- \. Male or female adults (defined as e 18 years of age)
- \. ECOG performance status 0-1
- ... and 5 more (see full listing online)

### Exclusion (5)

- \. Any unresolved toxicity of Grade e2 from previous anti-cancer treatment, except for alopecia, neuropathy, or skin pigmentation changes. Participants with chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the study investigator and the Sponsor's Medical Monitor.
- \. Known or suspected brain metastases, or spinal cord compression, unless the condition has been treated, asymptomatic, and has been stable without requiring escalating doses of corticosteroids (equivalent to d10 mg/day prednisone) or anti-convulsant medications for at least four weeks prior for the first dose of investigational drug.
- \. Prior treatment with an ADC targeting EGFR and/or cMet (including VBC101)
- \. Prior treatment with any ADC carrying a TOP1i payload (including prior VBC101).
- \. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.

## Locations (5 total)

---

Start Midwest, Grand Rapids, Michigan, United States  
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States  
NEXT Oncology, San Antonio, Texas, United States  
... and 2 more locations